206 related articles for article (PubMed ID: 28272203)
1. Sarcoidosis associated with infliximab therapy in ulcerative colitis: A case report.
Gîlcă GE; Diaconescu S; Bălan GG; Timofte O; Ştefănescu G
Medicine (Baltimore); 2017 Mar; 96(10):e6156. PubMed ID: 28272203
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.
Fok KC; Ng WW; Henderson CJ; Connor SJ
J Crohns Colitis; 2012 Jul; 6(6):708-12. PubMed ID: 22398084
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
4. Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis.
Clemmensen K; Akrawi N; Stawowy M
Scand J Gastroenterol; 2015; 50(12):1508-11. PubMed ID: 26133362
[TBL] [Abstract][Full Text] [Related]
5. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
Allocca M; Fiorino G; Gilardi D; Preatoni P; Papa A; Peyrin-Biroulet L; Danese S
Curr Drug Targets; 2018; 19(7):748-756. PubMed ID: 27231106
[TBL] [Abstract][Full Text] [Related]
6. Development of pulmonary sarcoidosis in Crohn's disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review.
Kashima S; Moriichi K; Ando K; Ueno N; Tanabe H; Yuzawa S; Fujiya M
BMC Gastroenterol; 2021 Oct; 21(1):373. PubMed ID: 34641810
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
Mizoshita T; Katano T; Tanida S; Hirano A; Miyaki T; Ozeki K; Suzuki Y; Sugimura N; Kataoka H; Joh T
Medicine (Baltimore); 2017 Aug; 96(32):e7800. PubMed ID: 28796080
[TBL] [Abstract][Full Text] [Related]
8. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
9. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in the treatment of steroid-dependent ulcerative colitis.
Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
[TBL] [Abstract][Full Text] [Related]
12. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
Mahmoud R; van Lieshout C; Frederix GWJ; Jharap B; Oldenburg B
J Crohns Colitis; 2021 May; 15(5):709-718. PubMed ID: 33125060
[TBL] [Abstract][Full Text] [Related]
13. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
14. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone.
Parihar V; Maguire S; Shahin A; Ahmed Z; O'Sullivan M; Kennedy M; Smyth C; Farrell R
Ir J Med Sci; 2016 Nov; 185(4):965-967. PubMed ID: 26358724
[TBL] [Abstract][Full Text] [Related]
15. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
Dumitrescu G; Dahan K; Treton X; Corcos O; Bouhnik Y; Stefanescu C
J Gastrointestin Liver Dis; 2015 Jun; 24(2):249-51. PubMed ID: 26114187
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
[TBL] [Abstract][Full Text] [Related]
17. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
19. Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report.
Parra RS; Feitosa MR; Machado VF; Ramalho LN; da Rocha JJ; Feres O
J Med Case Rep; 2015 Oct; 9():249. PubMed ID: 26518665
[TBL] [Abstract][Full Text] [Related]
20. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
